Edition:
United Kingdom

Xenetic Biosciences Inc (XBIO.OQ)

XBIO.OQ on NASDAQ Stock Exchange Capital Market

2.17USD
15 Dec 2017
Change (% chg)

$0.09 (+4.33%)
Prev Close
$2.08
Open
$2.06
Day's High
$2.19
Day's Low
$2.06
Volume
1,860
Avg. Vol
4,734
52-wk High
$5.90
52-wk Low
$1.75

Chart for

About

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company's platform technologies that enables the creation of drug therapies primarily for orphan indications. The... (more)
No analyst recommendations are available for .

Overall

Beta: 1.30
Market Cap(Mil.): $25.89
Shares Outstanding(Mil.): 8.72
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Xenetic Biosciences qtrly ‍loss per share $0.26​

* Xenetic Biosciences Inc- ‍current cash position is about $8.0 million, sufficient to fund operations through Q2 of 2018​‍​ Source text for Eikon: [ID: nBw9dWFZHa] Further company coverage:

15 Nov 2017

BRIEF-Xenetic Biosciences enters into sublicense agreement with subsidiary of Shire Plc

* Xenetic Biosciences enters into sublicense agreement related to its Polyxen technology with Baxalta Inc., a wholly-owned subsidiary of Shire Plc

02 Nov 2017

BRIEF-XENETIC BIOSCIENCES PROVIDES UPDATE ON ANNUAL MEETING OF STOCKHOLDERS

* XENETIC BIOSCIENCES PROVIDES UPDATE ON ANNUAL MEETING OF STOCKHOLDERS

02 Oct 2017

BRIEF-Xenetic Biosciences reports Q2 loss per share $0.34

* Xenetic biosciences reports 2017 second quarter financial results and provides business update

15 Aug 2017

BRIEF-Xenetic Biosciences commences patient enrollment in phase 2 study evaluating XBIO-101 in conjunction with Progestin therapy for the treatment of endometrial cancer

* Xenetic Biosciences commences patient enrollment in phase 2 study evaluating XBIO-101 in conjunction with Progestin therapy for the treatment of endometrial cancer

26 Jun 2017

Competitors

Earnings vs. Estimates